ZVRA Stock Analysis: Buy, Sell, or Hold?
ZVRA - Zevra Therapeutics, Inc. Common Stock
$13.06
-0.12 (-0.91%)
▼
5d:
-9.56%
30d:
+0.69%
90d:
+34.36%
HOLD
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
27d
Get Alerted When ZVRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ZVRA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ZVRA is fairly valued with market pricing in 2.0% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: ZVRA is fairly valued with market pricing in 2.0% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.82
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$7.96
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZVRA is currently trading at $13.06, which is considered fair relative to its 30-day fair value range of $11.85 to $14.06. The stock's valuation (Forward PE: 10.9) is in line with its historical norms (10.3). At these levels, the market is pricing in 2.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ZVRA is in a strong uptrend. The price is currently testing key support at $12.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.89 (+113.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ZVRA is in a strong uptrend. The price is currently testing key support at $12.85. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.89 (+113.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$11.85 -
$14.06
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
Protect Your Profits
Holding ZVRA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 113.5% below Wall St target ($27.89)
- NEUTRAL: Market pricing in 2.0% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -9.6% 5-day decline
Trading Range Analysis
30-Day Trading Range
$11.85 -
$14.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$12.85
Resistance Level
$15.04
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.93
Wall Street Target
$27.89
(+113.5%)
Revenue Growth (YoY)
77.5%
Profit Margin
101.6%
Valuation Premium vs History
+2.0% premium
PE vs Historical
10.9 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.0%
(market-implied from PE analysis)
1-Year Target
$13.32
(+2%)
2-Year Target
$13.59
(+4%)
3-Year Target
$13.86
(+6%)
3-Yr Target (if PE normalizes)
(PE: 11→10)
PE COMPRESSION
$13.06
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -2.3%)
$24.26
(+86%)
Base:
(SPY PE: 10.9, Growth: -2.3%)
$12.17
(-7%)
Bear:
(PE: 9.3, Growth: -2.3%)
$10.35
(-21%)
📈
Valuation based on Current Earnings
Trailing PE: 6.64 | Current EPS (TTM): $2.01
Bull Case
$8.73
(-34%)
Analyst growth -40.5%, PE expands to 7.3
Base Case
$7.94
(-40%)
Market implied -40.5%, PE stable at 6.6
Bear Case
$9.08
(-31%)
Severe decline -20.0%, PE contracts to 5.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 5:20 PM ET
Data refreshes hourly during market hours. Next update: 6:20 PM
Data refreshes hourly during market hours. Next update: 6:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZVRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Joshua Schafer
SELL
10500 shares
2026-02-03
Timothy J Sangiovanni
SELL
3000 shares
2026-02-03
Neil F Mcfarlane
SELL
91000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
Advanced ZVRA Option Strategies
Professional options setups generated by AI based on today's ZVRA price and gamma walls.
